{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the CI could not be estimated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"3.68","upperLimit":"NA","value":"9.4"},{"groupId":"OG001","lowerLimit":"5.78","upperLimit":"9.92","value":"9.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"MEDIAN","populationDescription":"All participants with mCRPC who achieved a confirmed complete or partial response to study treatment. No participants in the control group had a complete or partial response. Participants in Part 2 did not have mCRPC, so were not eligible for response using PCWG3 criteria.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.","title":"Part 1: Median Duration of Response (DoR) Per PCWG3 Criteria as Determined by the Investigator","type":"SECONDARY","unitOfMeasure":"months"}